Add to a list

Inactive Instrument

Northwest Biotherapeutics, Inc. Stock Other OTC

NWBO

US66737P6007

Biotechnology & Medical Research

OTC Markets Traded

Valuation: Northwest Biotherapeutics, Inc.

Market Cap	286M 245M 229M 210M 394M 27.39B 399M 2.71B 1.06B 13.76B 1.08B 1.05B 45.51B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	382M 328M 306M 281M 526M 36.59B 533M 3.62B 1.41B 18.38B 1.44B 1.4B 60.79B	EV / Sales 2026 *	-	EV / Sales 2027 *	10.6x
Free-Float	95.22%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news : Northwest Biotherapeutics, Inc.

15/08	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07/08	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
09/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
16/05	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/04	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
16/04	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
15/11	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/11	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
01/11/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
24/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
27/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI

More news

Press Releases: Northwest Biotherapeutics, Inc.

15/08	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
07/08	Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company	PR
09/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
03/07	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
16/05	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ

More press releases

Managers and Directors: Northwest Biotherapeutics, Inc.

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

More insiders

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC.	-6.38%	-8.82%	-	-	286M
WUXI APPTEC CO., LTD.	-3.00%	+2.27%	+77.60%	+109.33%	72.12B
ARGENX SE	+1.90%	+23.53%	+56.60%	+97.76%	65.85B
BIONTECH SE	+5.12%	+25.22%	+5.24%	-0.82%	29.28B
INSMED INCORPORATED	+0.55%	+1.64%	-5.15%	+471.68%	27.47B
WUXI BIOLOGICS (CAYMAN) INC.	+2.74%	+12.98%	+62.84%	+28.14%	26.7B
GENMAB A/S	+0.47%	+6.12%	+36.66%	-13.79%	20.06B
PHARMAESSENTIA CORPORATION	+1.82%	-6.67%	+247.46%	+393.10%	18.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.94%	+3.36%	+18.55%	+532.94%	16.4B
EXELIXIS, INC.	+0.73%	+5.54%	+39.71%	+153.07%	13.4B
Average	+0.49%	+8.36%	+59.94%	+196.82%	32.17B
Weighted average by Cap.	+0.73%	+9.48%	+59.05%	+157.80%

	2026 *	2027 *
Net sales	-	38.93M 33.35M 31.21M 28.57M 53.61M 3.73B 54.32M 369M 144M 1.87B 146M 143M 6.19B
Net income	-	-
Net Debt	96.08M 82.3M 77.01M 70.49M 132M 9.19B 134M 910M 355M 4.62B 361M 353M 15.27B	125M 107M 100M 91.66M 172M 11.95B 174M 1.18B 461M 6B 469M 459M 19.86B

Northwest Biotherapeutics, Inc. Stock Other OTC

Stocks

NWBO

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc.

Latest news : Northwest Biotherapeutics, Inc.

Press Releases: Northwest Biotherapeutics, Inc.

Quotes and Performance

Managers and Directors: Northwest Biotherapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile